Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Is the Current and Projected Market Size of the Cell-Based Ophthalmic Therapies Industry?#_x000D_
In the last few years, the market size for cell-based ophthalmic therapies has seen a significant increase. It is projected to expand from $1.22 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 21.1%. The surge experienced in the historical period is due to factors such as the escalating frequency of eye conditions, growing need for vision restoration, the expanding adoption of regenerative medicine, an increase in instances of age-related degeneration, and augmenting investments in clinical trials._x000D_
_x000D_
The market for cell-based ophthalmic treatments is predicted to undergo massive expansion in the coming years, reaching a valuation of $3.14 billion in 2029 with a compound annual growth rate (CAGR) of 20.7%. The anticipated growth during this period can be linked to the increasing success of cell therapies, the surge in global healthcare expenditure, the expanding elderly patient demographic, an innovative product pipeline, and the growing application of stem cells. Key trends expected to shape the forecast period encompass advancements in stem cell and gene-editing technologies, the establishment of targeted drug delivery systems, groundbreaking strides in regenerative medicine aimed at repairing retinal and corneal tissues, progress in biomaterials which boost cell therapy effectiveness and safety, and the creation of worldwide partnerships._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27246&type=smp_x000D_
_x000D_
#Which Factors Are Currently Driving The Growth Of The Cell-Based Ophthalmic Therapies Market?_x000D_
The rise in ophthalmic disorders is anticipated to fuel the expansion of the cell-based ophthalmic therapies market in the future. These disorders pertain to ailments or conditions affecting the eyes, leading to vision issues or damage to the health of the eye. The increased risk of age-related eye diseases among the aging population is causing a surge in these disorders, leading to vision loss due to extended life expectancy. Cell-based ophthalmic therapies work by mending or replacing damaged retinal and eye cells, thus restoring sight and preventing additional damage while encouraging regeneration and improving the overall function of the eye. For example, in September 2023, the Association of Optometrists, a representative membership organization based in the UK, reported that England had seen 22,552 new visual impairment certifications in 2022. Included in these were 1,344 from diabetic eye disease, 3,614 due to glaucoma, and 10,865 as a result of age-related macular degeneration. Hence, the rise in ophthalmic disorders is spurring the expansion of the cell-based ophthalmic therapies market._x000D_
_x000D_
#How Is The Global Cell-Based Ophthalmic Therapies Market Structured In Terms Of Segments?#_x000D_
The cell-based ophthalmic therapies market covered in this report is segmented_x000D_
_x000D_
1) By Therapy Type: Stem Cell Therapy, Gene Therapy, Tissue Engineering_x000D_
2) By Application: Retinal Disorders, Corneal Disorders, Glaucoma, Other Applications_x000D_
3) By End-User: Hospitals, Ophthalmic Clinics, Research Institutes, Other End-Users_x000D_
_x000D_
Subsegment:_x000D_
1) By Stem Cell Therapy: Embryonic Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Retinal Pigment Epithelium Cell Therapy, Limbal Stem Cell Therapy_x000D_
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector Based Gene Therapy, In-Vivo Gene Therapy, Ex-Vivo Gene Therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Therapy_x000D_
3) By Tissue Engineering: Bioengineered Corneal Tissue, Amniotic Membrane Transplantation, Hydrogel-Based Scaffolds, Synthetic Polymer Scaffolds, Decellularized Tissue Constructs_x000D_
_x000D_
#What Trends Are Currently Influencing Growth In The Cell-Based Ophthalmic Therapies Market?#_x000D_
Large corporations within the cell-based ophthalmic therapies market are turning their focus on developing progressive treatment methods, such as allogeneic cell therapy, to tackle the unaddressed aspects of treating corneal endothelial diseases. Allogeneic cell therapy is a treatment approach that uses stem cells or other cells donated by a genetically varied individual from the same species to mend or restore damaged tissues or to treat diseases. For example, in September 2024, Aurion Biotech, Inc., an American clinical-stage biotechnology firm, declared the commercial launch of Vyznova (neltependocel) in Japan. This product is developed to treat bullous keratopathy, an impairing condition of the corneal endothelium. Vyznova is thought to be the initial approved allogeneic cell therapy aimed specifically at corneal endothelial disease, having attained both regulatory and reimbursement approvals in Japan._x000D_
_x000D_
#Who Are The Main Participants Shaping The Cell-Based Ophthalmic Therapies Market Landscape?#_x000D_
Major companies operating in the cell-based ophthalmic therapies market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Astellas Pharma Inc., Sumitomo Pharma Co. Ltd., Healios K.K., Lineage Cell Therapeutics, Pandorum Technologies Pvt. Ltd., ActualEyes Inc., Neurotech Pharmaceuticals Inc., Coave Therapeutics SAS, jCyte Inc., Eyestem Research Pvt. Ltd., Opsis Therapeutics, Regenerative Patch Technologies LLC, Emmetrope Ophthalmics LLC, GenSight Biologics S.A., MEDIPOST Co. Ltd., Riken, Luxa Biotechnology Inc. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#Which Region Currently Holds The Largest Share In The Cell-Based Ophthalmic Therapies Market?#_x000D_
North America was the largest region in the cell-based ophthalmic therapies market in 2024. The regions covered in the cell-based ophthalmic therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27246&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model